Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OSUR 
OraSure Technologies Inc (OSUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: OSUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.67
1 Year Target Price $4.67
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.72% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 224.40M USD | Price to earnings Ratio - | 1Y Target Price 4.67 |
Price to earnings Ratio - | 1Y Target Price 4.67 | ||
Volume (30-day avg) 4 | Beta 0.44 | 52 Weeks Range 2.36 - 4.92 | Updated Date 07/1/2025 |
52 Weeks Range 2.36 - 4.92 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -19.77% | Operating Margin (TTM) -61.02% |
Management Effectiveness
Return on Assets (TTM) -4.8% | Return on Equity (TTM) -7.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -8592607 | Price to Sales(TTM) 1.39 |
Enterprise Value -8592607 | Price to Sales(TTM) 1.39 | ||
Enterprise Value to Revenue 0.25 | Enterprise Value to EBITDA 2.22 | Shares Outstanding 74800096 | Shares Floating 71113981 |
Shares Outstanding 74800096 | Shares Floating 71113981 | ||
Percent Insiders 4.83 | Percent Institutions 89.58 |
Analyst Ratings
Rating 2 | Target Price 4.67 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OraSure Technologies Inc
Company Overview
History and Background
OraSure Technologies Inc. was founded in 1988. Initially focused on specimen collection devices, it evolved to specialize in point-of-care diagnostic tests, particularly in infectious diseases and substance abuse.
Core Business Areas
- Molecular Solutions: This segment focuses on developing, manufacturing, and selling products for molecular sample collection, stabilization, and transport. This includes their Oragene product line.
- Infectious Disease: This segment concentrates on rapid diagnostic tests for infectious diseases like HIV and Hepatitis C. Key product is the OraQuick In-Home HIV Test.
- Other: Other product lines include substance abuse testing products.
Leadership and Structure
The leadership team includes President and CEO Lisa M. Michelson. The organizational structure is divided by business segments, with functional departments supporting each segment.
Top Products and Market Share
Key Offerings
- OraQuick In-Home HIV Test: An over-the-counter rapid HIV test providing results in 20 minutes. OraSure has a significant market share in the US at-home HIV testing market. Competitors include at-home testing kits from other diagnostic companies.
- Oragene DNA Collection Kits: Kits used for non-invasive collection of DNA from saliva for genetic testing and research. Used by direct to consumer genetic companies. Competitors include DNA Genotek (part of OraSure Technologies)
- InteliSwab COVID-19 Rapid Test: A rapid, point-of-care diagnostic test for COVID-19. Competition is intense in this market from companies like Abbott (ABT) and QuidelOrtho (QDEL).
Market Dynamics
Industry Overview
The diagnostics industry is driven by technological advancements, increasing healthcare awareness, and rising incidence of infectious diseases. The COVID-19 pandemic significantly impacted the market. Point of care solutions are increasingly desired. The global infectious disease diagnostics market is expected to grow significantly over the next decade.
Positioning
OraSure is positioned as a provider of convenient and accessible diagnostic solutions, focusing on oral fluid-based testing. Its competitive advantage lies in its proprietary collection technology and established brand recognition for at-home testing.
Total Addressable Market (TAM)
The total addressable market is in the billions of dollars, encompassing molecular diagnostics, infectious disease testing, and substance abuse testing. OraSure addresses this TAM with its specific product offerings.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in at-home testing
- Proprietary oral fluid collection technology
- Established distribution network
- Focus on key infectious diseases
Weaknesses
- Reliance on a few key products
- Competition from larger diagnostic companies
- Fluctuations in demand based on disease outbreaks
- Need for continuous innovation
Opportunities
- Expanding into new markets and geographies
- Developing new diagnostic tests for emerging diseases
- Partnerships and collaborations with other healthcare providers
- Increased adoption of at-home testing
Threats
- Intense competition from established players
- Changing regulatory landscape
- Technological disruptions in diagnostics
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- Abbott (ABT)
- QuidelOrtho (QDEL)
- Danaher (DHR)
Competitive Landscape
OraSure faces competition from larger, more diversified diagnostic companies. Its advantage lies in its niche focus and proprietary technology. However, it needs to innovate to maintain its competitive edge.
Major Acquisitions
CoreBiome
- Year: 2020
- Acquisition Price (USD millions): 19.5
- Strategic Rationale: Acquisition of CoreBiome expanded OraSureu2019s molecular collection business with microbiome collection and analysis capabilities.
Growth Trajectory and Initiatives
Historical Growth: OraSure's historical growth has been influenced by product development, market expansion, and disease outbreaks such as COVID-19.
Future Projections: Future growth projections are subject to analyst estimates and depend on the company's ability to innovate and capture market share.
Recent Initiatives: Recent initiatives include expanding product offerings, entering new partnerships, and strengthening its position in key markets.
Summary
OraSure Technologies is a niche player in the diagnostics market, leveraging its oral fluid collection technology. It holds a strong position in at-home testing but faces intense competition from larger players. The company needs to innovate and expand its product portfolio to sustain long-term growth. Recent acquisitions have helped to diversify the business, and capitalizing on new markets will be key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OraSure Technologies Inc
Exchange NASDAQ | Headquaters Bethlehem, PA, United States | ||
IPO Launch date 1986-11-12 | President, CEO & Director Ms. Carrie Eglinton Manner | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 501 | Website https://www.orasure.com |
Full time employees 501 | Website https://www.orasure.com | ||
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is h
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.